Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VXCL VAXCEL INC -- Ignore unavailable to you. Want to Upgrade?

To: Joe Copia who wrote (3)	5/6/1998 1:09:00 AM
From: Earl Falwell	Read Replies (1) \| Respond to of 22

Joe, This one looks interesting. I will be starting my DD this week and hope to add some input here. Vanderbilt University is involved and CYTR owns how much percent?. Hmmmmmmmm...... Earl

To: Joe Copia who wrote (3)	5/6/1998 9:13:00 AM
From: xclently	Respond to of 22

Through recent acquisitions and their relationship with CytRx (CYTR), VXCL is in a position to benefit from the drive to maximize the effectiveness of agents and speed-up their action with delivery agents, a key aspect of their portfolio.... (related excerpts from the 10k -- available at freedgar.com...must type in company name "Vaxcel", not the ticker symbol) PATENTS AND PROPRIETARY TECHNOLOGY-- Vaxcel actively seeks patent protection for its technologies, processes, uses, and ongoing improvements and considers its patents and other intellectual property to be critical to its business. Vaxcel has received a worldwide, exclusive licensefrom CytRx for the use of a series of certain copolymers as a vaccine adjuvant/delivery system. See Item 13 - "Certain Relationships and Related Transactions." These patents and patent applications contain claims directed to the use of copolymers as vaccine adjuvants/delivery systems and the use of the copolymers in any vaccine preparation. The compositions and methods for the administration of bioactive agents to and through the Peyer's Patches by means of microencapsulation in biocompatible, biodegradable microspheres of 1-10 microns in diameter are protected by issued patents, pending United States patent applications, and foreign counterparts held by Southern Research Institute ("SRI") and the University of Alabama at Birmingham ("UAB"). By means of the Merger with Zynaxis, this microencapsulation technology is exclusively licensed to Vaxcel in the field of oral vaccine delivery. See Item 13 - "Certain Relationships and Related Transactions." More to come ...